☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
maa
Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo
October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma
October 29, 2021
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma
October 1, 2021
Argenx Reports EMA's Validation of MAA for Efgartigimod to Treat Generalized Myasthenia Gravis
August 25, 2021
Gilead Reports EMA's Validation of MAA for Lenacapavir to Treat HIV-1 in People with Limited Therapy Options
August 20, 2021
BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell...
August 17, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.